U.S. Markets close in 22 mins

Voyager Therapeutics, Inc. (VYGR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
11.11+0.12 (+1.09%)
As of 3:38PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close10.99
Open10.90
Bid11.11 x 800
Ask11.13 x 800
Day's Range10.79 - 11.34
52 Week Range6.26 - 23.50
Volume143,597
Avg. Volume319,164
Market Cap413.189M
Beta (5Y Monthly)1.82
PE Ratio (TTM)N/A
EPS (TTM)-1.11
Earnings DateAug 10, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est22.85
  • The Daily Biotech Pulse: Voyager, AbbVie End Collaboration, Thumbs Down For DBV's Peanut Allergy Patch, Tiziana Expedites COVID-19 Trial Plans
    Benzinga

    The Daily Biotech Pulse: Voyager, AbbVie End Collaboration, Thumbs Down For DBV's Peanut Allergy Patch, Tiziana Expedites COVID-19 Trial Plans

    Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 3) * ABIOMED, Inc. (NASDAQ: ABMD) * ALX Oncology Holdings Inc (NASDAQ: ALXO) * Annexon Inc (NASDAQ: ANNX) * Atossa Therapeutics Inc (NASDAQ: ATOS) * Axonics Modulation Technologies Inc (NASDAQ: AXNX) * Catalent Inc (NYSE: CTLT) * Co-Diagnostics Inc (NASDAQ: CODX) (announced FDA emergency use authorization for a third-party self-administered test that uses the company's technology) * DexCom, Inc. (NASDAQ: DXCM) * Emergent Biosolutions Inc (NYSE: EBS) * Fulgent Genetics Inc (NASDAQ: FLGT) * Hologic, Inc. (NASDAQ: HOLX) * Immunic Inc (NASDAQ: IMUX) (reported positive midstage results for its multiple sclerosis drug) * Immunomedics, Inc. (NASDAQ: IMMU) * Inozyme Pharma Inc (NASDAQ: INZY) * ITAMAR MED LTD/S ADR (NASDAQ: ITMR) * NeoGenomics, Inc. (NASDAQ: NEO) * Novavax, Inc. (NASDAQ: NVAX) * OraSure Technologies, Inc. (NASDAQ: OSUR) * Penumbra Inc (NYSE: PEN) * Quidel Corporation (NASDAQ: QDEL) * Repligen Corporation (NASDAQ: RGEN) * Trevena Inc (NASDAQ: TRVN) * Varian Medical Systems, Inc. (NYSE: VAR) (announced a deal to be bought by Siemens Healthineers for $16.4 billion) * West Pharmaceutical Services Inc. (NYSE: WST) * Zoetis Inc (NYSE: ZTS)Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 30) * Legend Biotech Corp (NASDAQ: LEGN) (announced resignation of its CEO) * Natus Medical Inc (NASDAQ: NTUS) (reacted to its second-quarter results) * Pandion Therapeutics Holdco LLC (NASDAQ: PAND) * Verrica Pharmaceuticals Inc (NASDAQ: VRCA)Stocks In Focus Voyager, AbbVie Terminate Vectorized Antibody Collaborations Voyager Therapeutics Inc (NASDAQ: VYGR) announced the termination of its tau and alpha-synuclein vectorized antibody collaborations with AbbVie Inc (NYSE: ABBV). Voyager said it now retains full rights to the vectorization technology and certain novel vectorized antibodies developed as part of the collaborations.The research collaborations -- announced in 2018 and 2019, respectively -- called for Voyager to receive upfront payments for conducting research and preclinical studies.Voyager said it does not expect its cash runway guidance to be impacted due to the termination.Voyager shares were down 10.41% at $10.15 in Tuesday's premarket session.Tiziana Expedites Clinical Trial Plans For COVID-19 Treatment TIZIANA LF SCIE/S ADR (NASDAQ: TLSA) said it has signed agreements with four CROs to expedite clinical development of TZLS-501, a novel fully human anti-interleukin-6 receptor monoclonal antibody for the treatment of COVID-19 patients. Tiziana expects to commence the clinical study in the first quarter of 2021.In premarket trading Tuesday, Tiziana shares were rallying 9.49% to $6.DBV's Peanut Allergy Patch Slapped With Complete Response Letter DBV TECHNOLOGIE/S ADR (NASDAQ: DBVT) said the FDA has issued a Complete Response Letter regarding its BLA for investigational Viaskin Peanut, a non-invasive, once-daily epicutaneous patch to treat peanut allergies in children ages 4-11.In the letter, the FDA identified concerns regarding the impact of patch-site adhesion on efficacy and indicated the need for patch modifications and subsequently a new human factor study, the company said.Supplementary clinical data will need to be generated to support the modified patch, according to DBV, citing the FDA. In addition, the FDA requested additional Chemistry, Manufacturing and Controls data.The stock was slumping 34.39% to $2.69 in premarket trading Tuesday.See also: The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings Novartis Reports Positive Midstage Results For CAR-T Cell Therapy Novartis AG (NYSE: NVS) announced positive results from the Phase 2 ELARA trial of Kymriah in patients with relapsed or refractory follicular lymphoma.At the interim analysis, the global study met its primary endpoint of complete response rate, as assessed by independent review committee, Novartis said. No new Kymriah safety signals were observed, according to Novartis.Alterity Reports Positive Preclinical Results For Neurological Disorder Drug Alterity Therapeutics Ltd (NASDAQ: ATHE) said new data from an experiment testing its lead candidate ATH434 in an animal model of Multiple System Atrophy independently confirmed and extended previous findings demonstrating that ATH434 reduces α-synuclein pathology, preserves neurons and improves motor performance.View more earnings on IBBThe stock was skyrocketing 211.11% to $4.20 in premarket trading Tuesday.Karuna Not to Go Ahead With Evaluation of KarXT For Pain Following Failed Exploratory Study Karuna Therapeutics Inc (NASDAQ: KRTX) said topline results of an exploratory Phase 1b trial did not provide conclusive evidence of an analgesic benefit of KarXT on experimentally induced pain in healthy volunteers.The company said it will not proceed with the evaluation of KarXT for the treatment of pain.Earnings DURECT Corporation's (NASDAQ: DRRX) second-quarter revenues increased from $4 million to $14.3 million. The company reversed from a loss of 4 cents per share to a profit of 7 cents per share. Analysts, on average, estimated EPS of 1 cent.In premarket trading, the stock jumped 7.46% to $2.52.Pacific Biosciences of California Inc (NASDAQ: PACB) said its second-quarter revenues declined from $24.6 million in 2019 to $17.1 million in 2020. The loss per share narrowed from 16 cents to 15 cents, while the consensus estimate had called for 18 cents per share.The stock fell 5.37% to $3.70 in after-hours trading.Neurocrine Biosciences, Inc. (NASDAQ: NBIX) reported second-quarter revenues that increased from $183.5 million in 2019 to $302.4 million in 2020 on strong Ingrezza sales. Non-GAAP EPS increased from 71 cents to $1.42.The stock was up 3.25% to $127.01 premarket. Offerings Veracyte Inc (NASDAQ: VCYT) said it has commenced an underwritten public offering of 6 million shares of its common stock. All of the shares are being offered by the company.Veracyte intends to use the net proceeds from the offering for working capital and other general corporate purposes, and also for acquiring or investing in complementary businesses, technologies or other assets.The stock was down 3.09% premarket at $34.21. Achieve Life Sciences, Inc. (NASDAQ: ACHV) announced a proposed underwritten public offering in which it intends to offer shares of its common stock and, to certain investors, pre-funded warrants to purchase shares of common stock.The stock was down 8.28% premarket at $10.75. On The Radar Clinical Readouts BioSig Technologies Inc (NASDAQ: BSGM) CEO Kenneth Londoner will present at the Proactive Investors One2One Virtual Event with an update on a Phase 2 clinical study of merimepodib in combination with remdesivir in adult patients with advanced COVID-19.Earnings * Haemonetics Corporation (NYSE: HAE) (before the market open) * Incyte Corporation (NASDAQ: INCY) (before the market open) * Karyopharm Therapeutics Inc (NASDAQ: KPTI) (before the market open) * Intersect ENT Inc (NASDAQ: XENT) (before the market open) * Oxford Immunotec Global PLC (NASDAQ: OXFD) (before the market open) * Epizyme Inc (NASDAQ: EPZM) (before the market open) * Neuronetics Inc (NASDAQ: STIM) (before the market open) * Mallinckrodt PLC (NYSE: MNK) (before the market open) * Evofem Biosciences Inc (NASDAQ: EVFM) (before the market open) * Zimmer Biomet Holdings Inc (NYSE: ZBH) (before the market open) * Strongbridge Biopharma plc (NASDAQ: SBBP) (before the market open) * BIO-TECHNE Corp (NASDAQ: TECH) (before the market open) * Avanos Medical Inc (NYSE: AVNS) (before the market open) * Amarin Corporation plc (NASDAQ: AMRN) (before the market open) * Aquestive Therapeutics Inc (NASDAQ: AQST) (after the close) * Akcea Therapeutics Inc (NASDAQ: AKCA) (after the close) * Acorda Therapeutics Inc (NASDAQ: ACOR) (after the close) (after the close) * BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) (after the close) * Corcept Therapeutics Incorporated (NASDAQ: CORT) (after the close) * Xencor Inc (NASDAQ: XNCR) (after the close) * Vapotherm Inc (NYSE: VAPO) (after the close) * Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) (after the close) * NuVasive, Inc. (NASDAQ: NUVA) (after the close) * Qiagen NV (NYSE: QGEN) (after the close) * Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) (after the close) * Fulgent Genetics Inc (NASDAQ: FLGT) (after the close) * Enanta Pharmaceuticals Inc (NASDAQ: ENTA) (after the close) * Otonomy Inc (NASDAQ: OTIC) (after the close) * Inspire Medical Systems Inc (NYSE: INSP) (after the close) * Myokardia Inc (NASDAQ: MYOK) (after the close) * Curis, Inc. (NASDAQ: CRIS) (after the close) * CareDx Inc (NASDAQ: CDNA) (after the close) * Cardiovascular Systems Inc (NASDAQ: CSII) (after the close) * Cytosorbents Corp (NASDAQ: CTSO) (after the close) * GenMark Diagnostics, Inc (NASDAQ: GNMK) (after the close) * Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) (after the close) * Cerus Corporation (NASDAQ: CERS) (after the close) * Inspire Medical Systems Inc (NYSE: INSP) (after the close)Related Link: Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates See more from Benzinga * The Daily Biotech Pulse: Sanofi-GSK Land .1B Funding For Coronavirus Vaccine, D-Day For GW Pharma, FDA Nod For Roche(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • GlobeNewswire

    Voyager Therapeutics to Report Second Quarter 2020 Financial Results and Participate in Upcoming Investor Conferences

    CAMBRIDGE, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, will report its second quarter 2020 financial results and corporate updates on Monday, August 10, 2020, before the open of the U.S. financial markets. Additionally, the company will participate in the following virtual investor conferences in August: * BTIG Virtual Biotechnology Conference Monday, August 10 at 3:30 p.m. ET * Wedbush PacGrow Healthcare Virtual Conference Tuesday, August 11 at 1:10 p.m. ET * Canaccord Genuity 40th Annual Growth Conference Wednesday, August 12 at 3:30 p.m. ETThe webcast sessions may be accessed from the Investors & Media section of Voyager’s website at www.voyagertherapeutics.com. Replays of the webcasts will be archived on the Company's website for at least 30 days.About Voyager TherapeuticsVoyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Voyager is committed to advancing the field of AAV gene therapy through innovation and investment in vector engineering and optimization, manufacturing, and dosing and delivery techniques. Voyager’s wholly owned and partnered pipeline focuses on severe neurological diseases for which effective new therapies are needed, including Parkinson’s disease, Huntington’s disease, Friedreich’s ataxia, and other severe neurological diseases. For more information, please visit www.voyagertherapeutics.com or follow @VoyagerTx on Twitter and LinkedIn.Investor Relations:    Paul Cox VP, Investor Relations 857-201-3463 pcox@vygr.com   Media: Sheryl Seapy W2Opure 949-903-4750 sseapy@purecommunications.com

  • GlobeNewswire

    Voyager Therapeutics Provides Update on AbbVie Vectorized Antibody Collaborations

    CAMBRIDGE, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced the termination of its tau and alpha-synuclein vectorized antibody collaborations with AbbVie. Voyager retains full rights to the vectorization technology and certain novel vectorized antibodies developed as part of the collaborations. “Our efforts to harness AAV-based gene therapy to produce antibodies directly in the brain and overcome major limitations with delivery of current biologics across the blood-brain barrier have been highly productive,” said Omar Khwaja, M.D., Ph.D., Chief Medical Officer and Head of R&D at Voyager. “Through the tau and alpha-synuclein collaborations, we believe we have made considerable progress against targets for neurodegenerative diseases with this novel approach, reinforcing our enthusiasm for its potential to deliver therapeutically efficacious levels of biologics to the brain and central nervous system. We believe our continued work on discovery and design of novel AAV capsids with substantially improved blood-brain barrier penetrance will also considerably broaden the potential of AAV-based gene therapy, including vectorized antibodies or other biologics, for the treatment of severe neurological diseases.”The tau and alpha-synuclein research collaborations were formed in 2018 and 2019, respectively. Under the terms of the collaboration agreements, Voyager received upfront payments to perform research and preclinical development of vectorized antibodies directed against tau and alpha-synuclein. With the conclusion of the collaborations, Voyager has regained full clinical development and commercialization rights to certain product candidates developed within the context of the collaboration for the tau program. Voyager is free to pursue vectorized antibody programs for tau and alpha-synuclein alone or in collaboration with another partner.Voyager does not anticipate any changes to its cash runway guidance due to the termination of the agreements. As of March 31, 2020, the Company had cash, cash equivalents and marketable debt securities of $250.9 million, which, along with amounts expected to be received for reimbursement of development costs from Neurocrine Biosciences, is expected to be sufficient to meet Voyager’s projected operating expenses and capital expenditure requirements into mid-2022.About Voyager TherapeuticsVoyager Therapeutics is a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases. Voyager is committed to advancing the field of AAV gene therapy through innovation and investment in vector engineering and optimization, manufacturing, and dosing and delivery techniques. Voyager’s wholly owned and partnered pipeline focuses on severe neurological diseases for which effective new therapies are needed, including Parkinson’s disease, Huntington’s disease, Friedreich’s ataxia, and other severe neurological diseases. For more information, please visit www.voyagertherapeutics.com or follow @VoyagerTx on Twitter and LinkedIn.Forward-Looking StatementsThis press release contains forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as “may,” “might,” “will,” “would,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “undoubtedly,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward-looking statements. For example, all statements Voyager makes regarding the ability of Voyager to maintain research and development activities currently included within the collaboration agreements with AbbVie; Voyager’s ability to advance its AAV-based gene therapies and its ability to continue to develop its gene therapy platform; the scope of the intellectual property rights and other rights that will be available to Voyager following the termination of the AbbVie collaboration agreements;  the anticipated effects of the termination of the AbbVie collaboration agreements on Voyager’s anticipated financial results, including Voyager’s available cash, cash equivalents and marketable debt securities; and Voyager’s ability to fund its operating expenses with its current cash, cash equivalents and marketable debt securities through a stated time period are forward looking. All forward-looking statements are based on estimates and assumptions by Voyager’s management that, although Voyager believes such forward-looking statements to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Voyager expected. Such risks and uncertainties include, among others, the continued cooperation of AbbVie in activities arising from the termination of the AbbVie collaboration agreements, the development of the gene therapy platform; Voyager’s scientific approach and general development progress; Voyager’s ability to create and protect its intellectual property; and the sufficiency of Voyager’s cash resources. These statements are also subject to a number of material risks and uncertainties that are described in Voyager’s most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, as updated by its subsequent filings with the Securities and Exchange Commission. All information in the press release is as of the date of this press release, and any forward-looking statement speaks only as of the date on which it was made. Voyager undertakes no obligation to publicly update or revise this information or any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.Investors: Paul Cox VP, Investor Relations 857-201-3463 pcox@vygr.comMedia: Sheryl Seapy W2Opure 949-903-4750 sseapy@purecommunications.com